A double-blind, placebo-controlled study of Vigabatrin three g/day in patients with uncontrolled complex partial seizures

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Neurology

• Publication date

  1996-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.46.1.54PMID 8559421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy

  1993cited by this paper
• Gabapentin as add‐on therapy in refractory partial epilepsy

  1993cited by this paper
• Placebo‐controlled study of the efficacy and safety of lamotrigine in patients with partial seizures

  1993cited by this paper
• Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.

  1993cited by this paper
• Single-blind, placebo-controlled multicenter trial of vigabatrin in the treatment of epilepsy

  1992cited by this paper
• Effects of Vigabatrin on Cognitive Function and Mood When Used as Add‐on Therapy in Patients with Intractable Epilepsy

  1992cited by this paper
• Six‐year follow‐up study on the efficacy and safety of vigabatrin in patients with epilepsy

  1992cited by this paper
• Open, Double‐Blind and Long‐Term Study of Vigabatrin in Chronic Epilepsy

  1991cited by this paper
• Chronic Toxicity Studies with Vigabatrin, A GABA-Transaminase Inhibitor

  1990cited by this paper
• Revolution in medical records tracking.

  1990cited by this paper
• Old and new ways: family planning in Kenya.

  1989cited by this paper
• Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers.

  1989cited by this paper
• GABAergic mechanisms in the pathogenesis and treatment of epilepsy.

  1989cited by this paper
• Interaction between vigabatrin and phenytoin.

  1989cited by this paper
• Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy.

  1989cited by this paper
• Enzyme-activated/mechanism-based inhibitors.

  1987cited by this paper
• Double‐Blind Dose Reduction Study of Vigabatrin in Complex Partial Epilepsy

  1987cited by this paper
• Vigabatrin for refractory complex partial seizures

  1987cited by this paper
• A tribute to Lewis P. Rowland

  1987cited by this paper
• Vigabatrin in the Treatment of Epilepsy: A Double‐Blind, Placebo‐Controlled Study

  1986cited by this paper
• Report on the International League Against Epilepsy

  1986cited by this paper
• Double‐Blind, Placebo‐Controlled Study of Vigabatrin (Gamma‐Vinyl GABA) in Drug‐Resistant Epilepsy

  1986cited by this paper
• γ‐Vinyl GABA: A double‐blind placebo‐controlled trial in partial epilepsy

  1985cited by this paper
• The aging human brain

  1985cited by this paper
• Type II complex partial seizures: poor results of anterior temporal lobectomy.

  1984cited by this paper
• Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy.

  1984cited by this paper
• Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy.

  1984cited by this paper
• Biochemical and clinical effects of γ‐vinyl GABA in patients with epilepsy

  1984cited by this paper
• Increased gamma-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebrospinal fluid of patients treated with γ-vinyl GABA (4-amino-hex-5-enoic acid)

  1981cited by this paper
• Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl GABA (4-amino-hex-5-enoic acid).

  1981cited by this paper
• 4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain.

  1977cited by this paper

• Effectiveness and safety of single anti-seizure medication as adjunctive therapy for drug-resistant focal epilepsy based on network meta-analysis

  2025cites this paper
• The Road Not Taken: Misclassifying an Anti‐Seizure Medication as a Failure

  2025cites this paper
• Increased seizure frequency graphs in medication trials: FDA labels vs. peer-review.

  2025cites this paper
• Established and emerging GABAA receptor pharmacotherapy for epilepsy

  2024cites this paper
• Efficacy and safety of add‐on antiseizure medications for focal epilepsy: A network meta‐analysis

  2024cites this paper
• Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies

  2022cites this paper
• Neuropharmacology of Antiseizure Drugs

  2021cites this paper
• Efficacy and tolerability of antiseizure drugs

  2021cites this paper
• Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis

  2020cites this paper
• Amelioration of cerebral vasospasm and secondary injury by Vigabatrin following experimental subarachnoid hemorrhage in the rabbit.

  2020cites this paper
• Vigabatrin add-on therapy for drug-resistant focal epilepsy.

  2020influential citation
• Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials.

  2018cites this paper
• Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy

  2018cites this paper
• Pharmacotherapy for Focal Seizures in Children and Adolescents

  2018cites this paper
• Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy

  2018cites this paper
• Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy

  2018cites this paper
• Vigabatrin: Lessons Learned From the United States Experience

  2017cites this paper
• Evaluate the Efficacy and Safety of Anti‐Epileptic Medications for Partial Seizures of Epilepsy: A Network Meta‐Analysis

  2017cites this paper
• Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.

  2016cites this paper
• Retinal structure and function in vigabatrin‐treated adult patients with refractory complex partial seizures

  2016cites this paper
• Population dose‐response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures

  2015cites this paper
• Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models

  2014cites this paper
• Vigabatrin pediatric dosing information for refractory complex partial seizures: Results from a population dose–response analysis

  2014cites this paper
• Pharmacotherapy for tonic–clonic seizures

  2014cites this paper
• Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms

  2014cites this paper
• Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex.

  2013cites this paper
• Actualización de las guías para el tratamiento farmacológico de la epilepsia en adultos

  2013cites this paper
• In silico Analysis of Binding Interaction of Antiepileptic Drugs with GABA Receptor Associated Protein of Caenorhabditis elegans

  2013cites this paper
• Comparative efficacy and tolerability of anti‐epileptic drugs for refractory focal epilepsy: systematic review and network meta‐analysis reveals the need for long term comparator trials

  2013cites this paper
• Vigabatrin for refractory partial epilepsy.

  2013cites this paper
• Vigabatrin-associated Visual Field Loss

  2012cites this paper
• Vigabatrin for childhood partial-onset epilepsies.

  2012cites this paper
• Placebo‐corrected efficacy of modern nonenzyme‐inducing AEDs for refractory focal epilepsy: Systematic review and meta‐analysis

  2012cites this paper
• Fragile X Syndrome: The GABAergic System and Circuit Dysfunction

  2011cites this paper
• Registry initiated to characterize vision loss associated with vigabatrin therapy.

  2011cites this paper
• Safety and Efficacy of Vigabatrin for the Treatment of Infantile Spasms

  2011cites this paper
• Mechanism of action of vigabatrin: correcting misperceptions

  2011cites this paper
• Vigabatrin therapy for refractory complex partial seizures: review of clinical trial experience in the United States

  2011influential citation
• Epilepsy: Five New Things

  2011cites this paper
• Non‐vision adverse events with vigabatrin therapy

  2011influential citation
• Peripapillary retinal nerve fibre layer thickness in individuals with epilepsy exposed to vigabatrin

  2011cites this paper
• Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema.

  2011cites this paper
• Balancing clinical benefits of vigabatrin with its associated risk of vision loss

  2011cites this paper
• Inhibitory neurotransmission in the Fmr1 knockout mouse model of Fragile X Syndrome : region- and circuit-specific deficits

  2011cites this paper
• Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta‐analysis

  2011cites this paper
• Placebo‐corrected efficacy of modern antiepileptic drugs for refractory epilepsy: Systematic review and meta‐analysis

  2010cites this paper
• Fisiopatología de la epilepsia del lóbulo temporal: revisión del proceso de muerte neuronal a la neuroplasticidad

  2010cites this paper
• New drugs for pediatric epilepsy.

  2010cites this paper
• Vigabatrin in Refractory Complex Partial Seizures: The Evidence of its Therapeutic Value

  2010influential citation
• Recommendations for visual evaluations of patients treated with vigabatrin

  2010cites this paper
• Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.

  2010cites this paper
• Flexible dosing of adjunctive zonisamide in the treatment of adult partial‐onset seizures: a non‐comparative, open‐label study (ZEUS)

  2010cites this paper
• Placebo responses in randomized trials of antiepileptic drugs.

  2010cites this paper
• New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin

  2010cites this paper
• Evidence-based Review of Recommendations for Visual Function Testing in Patients Treated with Vigabatrin

  2010cites this paper
• Epilepsy New Antiepileptic Drugs : Lacosamide , Rufinamide , and Vigabatrin

  2010cites this paper
• New drugs approved in 2009.

  2010cites this paper
• Vigabatrin: 2008 Update

  2009cites this paper
• Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval

  2009cites this paper
• Study of visual field defects in patients with epilepsy receiving Vigabatrin

  2009cites this paper
• Treatment of refractory complex partial seizures: role of vigabatrin

  2009cites this paper
• Treatment of refractory complex partial seizures: role of vigabatrin

  2009cites this paper
• Bilateral Paramedian Thalamic and Mesencephalic Infarcts in a Newborn Due to Occlusion of the Artery of Percheron

  2009cites this paper
• Vigabatrin extracellular pharmacokinetics and concurrent γ‐aminobutyric acid neurotransmitter effects in rat frontal cortex and hippocampus using microdialysis

  2009cites this paper
• Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy

  2009influential citation
• Evaluating Risks for Vigabatrin Treatment

  2009cites this paper
• CNS Adverse Events Associated with Antiepileptic Drugs

  2008cites this paper
• Treatment of epilepsy: the GABA‐transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina

  2008cites this paper
• Vigabatrin for refractory partial epilepsy.

  2008cites this paper
• The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review.

  2006cites this paper
• Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures.

  2006cites this paper
• Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

  2005cites this paper
• Antiepileptic Drugs: Expanded Options and Improved Tolerance

  2004cites this paper
• Vigabatrin, the GABA‐transaminase inhibitor, damages cone photoreceptors in rats

  2004cites this paper
• Vigabatrin, the GABA-transaminase inhibitor, damages cone photoreceptors in rats.

  2004cites this paper
• Selection Criteria for the Clinical Use of the Newer Antiepileptic Drugs

  2003cites this paper
• Measuring the efficacy of antiepileptic drugs.

  2003cites this paper
• Therapeutics in pediatric epilepsy, Part 1: The new antiepileptic drugs and the ketogenic diet.

  2003cites this paper
• Pharmacokinetics of the S(+) and R(-) enantiomers of vigabatrin during chronic dosing in a patient with renal failure.

  2003cites this paper
• Visual functions in epilepsy patients on valproate monotherapy.

  2002cites this paper
• Occurrence of Psychosis in Patients with Epilepsy Randomized to Tiagabine or Placebo Treatment

  2002cites this paper
• Visual field constriction and electrophysiological changes associated with vigabatrin

  2002cites this paper
• Vigabatrin and retinal changes

  2002cites this paper
• Visual Function is Stable in Patients Who Continue Long‐Term Vigabatrin Therapy: Implications for Clinical Decision Making

  2001cites this paper
• GABAergic Mechanisms in Epilepsy

  2001cites this paper
• [Drug resistant partial seizures. therapeutic strategies in adults].

  2001cites this paper
• Vigabatrin

  2001cites this paper
• Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group.

  2000cites this paper
• New antiepileptic drugs.

  2000cites this paper
• Therapeutic Safety Monitoring: What to Look for and When to Look for It

  2000cites this paper
• Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group.

  2000cites this paper
• The Potential for Vigabatrin‐Induced Intramyelinic Edema in Humans

  2000cites this paper
• Treatment of Epilepsy in the New Millennium

  2000cites this paper
• New anti-epileptic drugs for the 21st century

  2000cites this paper
• Reversal of the activity-dependent suppression of GABA-mediated inhibition in hippocampal slices from gamma-vinyl GABA (vigabatrin)-pretreated rats.

  2000cites this paper
• Treatment of epilepsy in the multiply handicapped.

  2000cites this paper
• Overview of childhood epilepsy and epileptic syndromes and advances in therapy.

  2000cites this paper
• Management of epilepsy in adolescents and adults.

  2000cites this paper
• Vigabatrin Raman Sankar and

  1999cites this paper
• Managing Pediatric Epilepsy Syndromes With New Antiepileptic Drugs

  1999cites this paper